ATE431147T1 - Mittel zur behandlung des integrationsdysfunktionssyndroms - Google Patents

Mittel zur behandlung des integrationsdysfunktionssyndroms

Info

Publication number
ATE431147T1
ATE431147T1 AT03792731T AT03792731T ATE431147T1 AT E431147 T1 ATE431147 T1 AT E431147T1 AT 03792731 T AT03792731 T AT 03792731T AT 03792731 T AT03792731 T AT 03792731T AT E431147 T1 ATE431147 T1 AT E431147T1
Authority
AT
Austria
Prior art keywords
symptoms
schizophrenia
agents
dysfunction syndrome
integration dysfunction
Prior art date
Application number
AT03792731T
Other languages
English (en)
Inventor
M Nakamura
M Ogasa
Shunsuke Sumitomo Sami
Original Assignee
Dainippon Sumitomo Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31946785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE431147(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dainippon Sumitomo Pharma Co filed Critical Dainippon Sumitomo Pharma Co
Application granted granted Critical
Publication of ATE431147T1 publication Critical patent/ATE431147T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrotherapy Devices (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT03792731T 2002-08-22 2003-08-20 Mittel zur behandlung des integrationsdysfunktionssyndroms ATE431147T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40492702P 2002-08-22 2002-08-22
PCT/JP2003/010490 WO2004017973A1 (ja) 2002-08-22 2003-08-20 統合失調症治療剤

Publications (1)

Publication Number Publication Date
ATE431147T1 true ATE431147T1 (de) 2009-05-15

Family

ID=31946785

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03792731T ATE431147T1 (de) 2002-08-22 2003-08-20 Mittel zur behandlung des integrationsdysfunktionssyndroms

Country Status (8)

Country Link
US (3) US9174975B2 (de)
EP (3) EP1535616B1 (de)
JP (1) JP4745661B2 (de)
AT (1) ATE431147T1 (de)
AU (1) AU2003257589A1 (de)
DE (1) DE60327634D1 (de)
ES (2) ES2326078T3 (de)
WO (1) WO2004017973A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1535616B1 (de) 2002-08-22 2009-05-13 Dainippon Sumitomo Pharma Co., Ltd. Mittel zur behandlung des integrationsdysfunktionssyndroms
KR101113630B1 (ko) 2003-06-23 2012-02-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 노인성 치매 치료제
US20070160537A1 (en) * 2004-02-20 2007-07-12 Takeo Ishiyama In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia
DK1884242T3 (da) * 2005-05-26 2013-05-06 Dainippon Sumitomo Pharma Co Farmaceutisk sammensætning omfattende lurasidon
WO2011093522A1 (en) * 2010-01-28 2011-08-04 Dainippon Sumitomo Pharma Co., Ltd. A cycloalkane derivative
US8258139B2 (en) * 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
JP2015502941A (ja) * 2011-12-02 2015-01-29 大日本住友製薬株式会社 少なくとも１つのｃｎｓ障害の治療、予防、および／または管理のためのルラシドン新規投与レジメンおよびその使用
JP6594351B2 (ja) 2014-06-16 2019-10-23 ジョンソン、マッセイ、パブリック、リミテッド、カンパニー 新規中間体を含むアルキル化アリールピペラジン及びアルキル化アリールピペリジン化合物の製造方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0464846A (ja) * 1990-07-05 1992-02-28 Matsushita Seiko Co Ltd Ｏａ機器用フード装置
JP2800953B2 (ja) * 1990-07-06 1998-09-21 住友製薬株式会社 新規なイミド誘導体
JP3211279B2 (ja) * 1990-10-08 2001-09-25 住友化学工業株式会社 高純度カルボン酸フェニルエステル類の製造方法
DK36291D0 (da) * 1991-03-01 1991-03-01 Lundbeck & Co As H Anvendelse af piperidylsubstituerede indolderivater til behandling af kognitive lidelser
GB9202915D0 (en) 1992-02-12 1992-03-25 Wellcome Found Chemical compounds
IL110011A (en) 1994-06-13 2004-09-27 Yeda Res & Dev Pharmacological preparations for the treatment of schizophrenia
WO1996014297A1 (en) 1994-11-04 1996-05-17 Sumitomo Pharmaceuticals Company, Limited Novel lactam derivatives
JP3775823B2 (ja) 1995-06-09 2006-05-17 大日本住友製薬株式会社 新規なイミド誘導体
EP1073432B1 (de) 1998-04-14 2007-08-15 The General Hospital Corporation Verwendung von d-serine oder d-alanine zur behandlung von schizophrenie
AU3783799A (en) * 1998-05-05 1999-11-23 Jose Pozuelo Compositions and methods for treating particular chemical addictions and mental illnesses
JP2000281576A (ja) 1999-03-29 2000-10-10 Sumitomo Pharmaceut Co Ltd イミド誘導体を含有するプロテオグリカン生成促進剤
AR027134A1 (es) 1999-12-30 2003-03-12 Lundbeck & Co As H Derivados de indol.
CA2422044A1 (en) 2000-09-14 2002-03-21 Gliatech, Inc. Nitrogen-containing compounds and their use as glycine transport inhibitors
JP4868695B2 (ja) * 2000-09-22 2012-02-01 大日本住友製薬株式会社 崩壊性が良好な経口製剤
CA2431041A1 (en) * 2001-01-02 2002-07-11 Pharmacia & Upjohn Company New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents
US6605155B2 (en) * 2001-02-21 2003-08-12 Seiwa Pro Co., Ltd. Remover for scale deposited on titanium material
EP1395257A1 (de) * 2001-06-12 2004-03-10 Elan Pharmaceuticals, Inc. Makrocyclische verbindungen zur behandlung der alzheimer-krankheit
JP4568463B2 (ja) 2001-11-05 2010-10-27 独立行政法人科学技術振興機構 ドレブリンａ発現抑制動物神経細胞及び非ヒトモデル動物
JP4175800B2 (ja) 2001-11-27 2008-11-05 住友化学株式会社 イミド誘導体の製造方法
EP1480629A1 (de) * 2002-02-08 2004-12-01 Abbott Laboratories Kombinationstherapie für die behandlung der schizophrenie
EP1535616B1 (de) 2002-08-22 2009-05-13 Dainippon Sumitomo Pharma Co., Ltd. Mittel zur behandlung des integrationsdysfunktionssyndroms
KR101113630B1 (ko) * 2003-06-23 2012-02-13 다이닛본 스미토모 세이야꾸 가부시끼가이샤 노인성 치매 치료제
US20070160537A1 (en) * 2004-02-20 2007-07-12 Takeo Ishiyama In vivo screening method of therapeutic agent for memory/learning dysfunctions by schizophrenia
US7122683B2 (en) * 2004-11-23 2006-10-17 Pfizer Inc. Amides useful as monoamine re-uptake inhibitors
TW200812993A (en) 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
CN101663308A (zh) * 2006-10-30 2010-03-03 桑尔克斯药品公司 N-甲基色胺钙五水合物(dcp)和基于它的治疗方法
CA2682494C (en) 2007-04-04 2011-10-11 Merck & Co., Inc. Hexahydro-1h-4,7-methanoisoindole-1,3-dione compounds for treating psychiatric disorders

Also Published As

Publication number Publication date
AU2003257589A1 (en) 2004-03-11
US9174975B2 (en) 2015-11-03
ES2326078T3 (es) 2009-09-30
EP2295061A1 (de) 2011-03-16
US9815827B2 (en) 2017-11-14
US20180051017A1 (en) 2018-02-22
JP4745661B2 (ja) 2011-08-10
EP1944030A1 (de) 2008-07-16
WO2004017973A1 (ja) 2004-03-04
DE60327634D1 (de) 2009-06-25
EP1535616B1 (de) 2009-05-13
ES2685780T3 (es) 2018-10-11
EP1944030B1 (de) 2018-08-01
EP1535616A4 (de) 2005-11-30
JPWO2004017973A1 (ja) 2005-12-08
US20060025422A1 (en) 2006-02-02
US20140371236A1 (en) 2014-12-18
EP1535616A1 (de) 2005-06-01

Similar Documents

Publication Publication Date Title
ATE375341T1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
BR0207526A (pt) Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
GB0318447D0 (en) Therapeutic agents
ATE482747T1 (de) Neue amide derivate und deren pharmazeutische verwendungen
DE60216830D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von Störungen des ZNS oder anderen Erkrankungen
RU2014122858A (ru) Лечение когнитивных расстройств (r)-7-хлор-n-(хинуклидин-3-ил)бензо[в]тиофен-2-карбосамидом и его фармацевтически приемлемыми солями
WO2005063745A8 (en) Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
EA200400881A1 (ru) Азаарилпиперазины
GB0222514D0 (en) Organic compounds
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
ATE431147T1 (de) Mittel zur behandlung des integrationsdysfunktionssyndroms
BR0211970A (pt) Uso de bibn4096 em combinação com outras drogas antienxaqueca para o tratamento de enxaqueca
NO20055531L (no) Preparat for forbedret kognisjon og hukommelse
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
EP1262197A3 (de) Kombinationstherapie zur Behandlung von Schlafstörungen, Schlaflosigkeit inbegriffen
PL1656131T3 (pl) Zastosowanie betainy w leczeniu chromania przestankowego
TW200616644A (en) Medicine for prevention or treatment of diabetes
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
EA200700178A1 (ru) Пептид, обладающий стресспротекторным действием, фармацевтическая композиция на его основе и способ ее применения
EA200701017A1 (ru) Применение рибозы-цистеина для лечения гипоксии
EA200601666A1 (ru) Комбинированная фармацевтическая композиция для ингибирования ухудшения когнитивных функций
SE0203778D0 (sv) A new oral immediated release dosage form
ATE447953T1 (de) Pharmazeutische zusammensetzungen zur behandlung von leishmaniasis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1535616

Country of ref document: EP